Scott Naisbitt is the Vice President of Scientific and Medical Affairs at Lutonix, a subsidiary of CR Bard. He was a founding board member of Lutonix, Inc. and was Chief Scientific Officer prior to the acquisition. Scott has over 13 years medical device, biopharmaceutical, and drug-device combination product development and venture capital experience. Scott led key scientific (clinical, preclinical, mechanism-of-action) strategy and discussions with physicians and regulatory bodies regarding a drug-device combination product resulting in the first FDA approved IDE for a drug coated balloon.
Prior to joining Lutonix, he was a principal and entrepreneur-in-residence at the healthcare fund RiverVest Venture Partners and an associate at the medical device incubator Seedling Enterprises. He worked in research labs at Harvard Medical School and Massachusetts General Hospital and has multiple peer-reviewed publications.
Education, Personal, and Fellowship
Scott holds a MD and PhD from the Harvard-MIT Division of Health Sciences and Technology and a BS in Physics and a BS in Mathematics (Gibson Award) from the University of Utah. He was awarded the NIH Medical Scientist Training Program Scholarship by Harvard Medical School.
Scott is a member of Kauffman Fellows Class 8 and served his fellowship under mentor Mark Mendel (KFP Charter Class member) at RiverVest Venture Partners in St. Louis, MO.